Browse Prior Art Database

Optimization of aerosol deposition in inhaled therapies delivered by mechanical ventilators: Diagnostic Tool

IP.com Disclosure Number: IPCOM000181441D
Publication Date: 2009-Apr-02
Document File: 7 page(s) / 61K

Publishing Venue

The IP.com Prior Art Database

This text was extracted from a Microsoft Word document.
This is the abbreviated version, containing approximately 18% of the total text.

Optimization of aerosol deposition in inhaled therapies
delivered by mechanical ventilators: Diagnostic Tool

 

 

  1. Principle

A software system is used for ascertaining the patient’s respiratory system morphology. This information would be used for (i) identifying the disease and especially the stage of the disease, using information about the effects of the disease on the lungs structure for furthering diagnosis, (ii) following-up the evolution of the disease and the efficiency of the treatment, and (iii) early detecting of a respiratory disease.

 

  1. General background

In is known to use of a software algorithm for individualizing and improving the efficiency of aerosol therapies. However, the efficiency of the treatment is usually improved via an iterative process performed by the physician, with the help of the patient. It did not address an optimization process or a device controlling; see Figure 3.

Hereafter, aerosol therapies include the treatment of respiratory disease by delivering inhaled drugs within the human lungs, e.g., bronchodilators for the treatment of asthma, and the systemic delivery of drugs for the treatment of non respiratory tract disease, e.g., aerosolized insulin for the treatment of diabetes. Also included in aerosol therapies is the treatment by aerosolized drugs of localized infection of the trachea due to invasive ventilation.

                                                  

  1. Motivation

Aerosol therapies could be improved if inhaled pharmaceuticals were delivered to appropriate sites within human lungs. Thus, targeting drugs deposition would enhance the efficiency of the treatment and diminish the negative effects.

In other words, inhaling aerosolized drugs can be an efficient treatment only if the drug particles reach the most desired regions of the lungs, i.e., the sites where the particles would be useful for treating the disease, e.g., the tracheobronchial (TB) compartment of the lungs for treating an asthmatic patient.

Thus the potential efficiency of a treatment can be estimated by comparison of the desired particle deposition sites and the real particle deposition pattern obtained when inhaling pharmaceutical drugs.

The desired particle deposition sites depend on the disease to treat and can be defined a priori by the physician.

The real particle deposition pattern obtained when inhaling drugs can not be measured or evaluated by the physician. Indeed it depends on many parameters (see below) and is governed by complex physical mechanisms such as fluid flow motion, particle deposition mechanisms, interaction between the carrier gaseous phase and the aerosolized drugs…

The parameters influencing the particle deposition pattern are: the patient’s respiratory system morphology (e.g., trachea diameter or length of the main bronchi), aerosol characteristics (e.g., particle size and carrier gas density), inh...